Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Idiopathic recurring stupor

P Tinuper1, P Montagna, G Plazzi

  • 1Institute of Neurology, University of Bologna, Italy.

Neurology
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clarifying main nutritional aspects and resting energy expenditure in children with Smith-Magenis syndrome.

European journal of pediatrics·2024
Same author

A comparative blind study between skin biopsy and seed amplification assay to disclose pathological α-synuclein in RBD.

NPJ Parkinson's disease·2023
Same author

Predicting the clinical trajectory of feeding and swallowing abilities in CHARGE syndrome.

European journal of pediatrics·2023
Same author

Nurse-led dexmedetomidine sedation for magnetic resonance imaging in children: a 6-year quality improvement project.

Anaesthesia·2023
Same author

Drooling outcome measures in paediatric disability: a systematic review.

European journal of pediatrics·2022
Same author

Consistent skin α-synuclein positivity in REM sleep behavior disorder - A two center two-to-four-year follow-up study.

Parkinsonism & related disorders·2021
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Idiopathic recurring stupor (IRS) may stem from excess endozepine-4, a benzodiazepine-like substance. Treatment with flumazenil, a benzodiazepine antagonist, effectively resolved symptoms in three patients.

Area of Science:

  • Neurology
  • Neuropharmacology
  • Endocrinology

Background:

  • Idiopathic recurring stupor (IRS) is a rare neurological disorder characterized by unexplained recurrent episodes of stupor.
  • The exact pathogenesis of IRS remains unknown, with no clear metabolic, toxic, or structural brain abnormalities identified in affected individuals.

Observation:

  • Three patients with IRS presented with recurrent stuporous states and unique electroencephalogram (EEG) findings during ictal periods.
  • EEG recordings showed fast (14- to 16-Hz), unreactive background activity, which is atypical for known causes of stupor.

Findings:

  • Administration of flumazenil, a specific benzodiazepine receptor antagonist, led to a rapid and complete resolution of both the clinical stupor and the abnormal EEG activity.
  • Plasma analysis during ictal episodes revealed significantly elevated levels of endozepine-4, a substance with benzodiazepine-like activity, in all three patients.

Related Experiment Videos

Implications:

  • These findings suggest that an overabundance of endozepine-4 may be the underlying cause of idiopathic recurring stupor.
  • This discovery opens new avenues for diagnosing and potentially treating IRS by targeting benzodiazepine receptor pathways or modulating endozepine levels.